[go: up one dir, main page]

NO20081724L - Stable pharmaceutical composition comprising a pyrimidine sulfamide - Google Patents

Stable pharmaceutical composition comprising a pyrimidine sulfamide

Info

Publication number
NO20081724L
NO20081724L NO20081724A NO20081724A NO20081724L NO 20081724 L NO20081724 L NO 20081724L NO 20081724 A NO20081724 A NO 20081724A NO 20081724 A NO20081724 A NO 20081724A NO 20081724 L NO20081724 L NO 20081724L
Authority
NO
Norway
Prior art keywords
stable pharmaceutical
pharmaceutical composition
sulfamide
pyrimidine
pyrimidine sulfamide
Prior art date
Application number
NO20081724A
Other languages
Norwegian (no)
Other versions
NO341325B1 (en
Inventor
Olivier Lambert
Lovelace Holman
Charles Tokunbo Adesuyi
Bruce Hamilton Lithgow
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37865339&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20081724(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of NO20081724L publication Critical patent/NO20081724L/en
Publication of NO341325B1 publication Critical patent/NO341325B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Oppfinnelsen vedrører stabile farmasøytiske sammensetninger omfattende forbindelsen med formelen under, eller farmasøytisk akseptable salter, solvater, hydrater eller morfologe former derav.The invention relates to stable pharmaceutical compositions comprising the compound of the formula below, or pharmaceutically acceptable salts, solvates, hydrates or morphological forms thereof.

NO20081724A 2005-09-12 2008-04-09 Stable pharmaceutical composition comprising a pyrimidine sulfamide NO341325B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2005009775 2005-09-12
PCT/IB2006/053210 WO2007031933A2 (en) 2005-09-12 2006-09-11 Stable pharmaceutical composition comprising a pyrimidine-sulfamide

Publications (2)

Publication Number Publication Date
NO20081724L true NO20081724L (en) 2008-04-09
NO341325B1 NO341325B1 (en) 2017-10-16

Family

ID=37865339

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081724A NO341325B1 (en) 2005-09-12 2008-04-09 Stable pharmaceutical composition comprising a pyrimidine sulfamide

Country Status (23)

Country Link
US (6) US20080233188A1 (en)
EP (2) EP1928409B1 (en)
JP (2) JP4955685B2 (en)
KR (1) KR101313395B1 (en)
CN (1) CN101262847B (en)
AU (1) AU2006290309B2 (en)
BR (1) BRPI0615898B8 (en)
CA (1) CA2621273C (en)
CY (1) CY1113395T1 (en)
DK (1) DK1928409T3 (en)
ES (1) ES2393117T3 (en)
HR (1) HRP20120957T1 (en)
IL (1) IL190072A (en)
MY (1) MY151003A (en)
NO (1) NO341325B1 (en)
NZ (1) NZ567188A (en)
PL (1) PL1928409T3 (en)
PT (1) PT1928409E (en)
RU (1) RU2424805C2 (en)
SI (1) SI1928409T1 (en)
TW (1) TWI323661B (en)
WO (1) WO2007031933A2 (en)
ZA (1) ZA200802947B (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101313395B1 (en) 2005-09-12 2013-10-02 액테리온 파마슈티칼 리미티드 Stable pharmaceutical composition comprising a pyrimidine-sulfamide
AR062501A1 (en) * 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd THERAPEUTIC COMPOSITIONS
TWI399223B (en) * 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd Solid dosage form of olmesartan and amlodipine
MX2010001837A (en) * 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd DERIVATIVES OF 4-PYRIMIDINASULFAMIDA.
KR20100132489A (en) * 2008-02-20 2010-12-17 액테리온 파마슈티칼 리미티드 Combination comprising paclitaxel to treat ovarian cancer
HUE047767T2 (en) * 2008-08-13 2020-05-28 Actelion Pharmaceuticals Ltd Therapeutic preparations containing macitentan
ES2543280T3 (en) * 2009-08-10 2015-08-17 Board Of Regents, The University Of Texas System Treatment of brain metastases with endothelin receptor inhibitors in combination with a cytotoxic chemotherapeutic agent
US10071059B2 (en) 2009-12-18 2018-09-11 Frieslandcampina Nederland Holding B.V. Co-processed tablet excipient composition its preparation and use
IT1403248B1 (en) * 2010-11-12 2013-10-17 Scharper Therapeutics Srl COMPOSITION FOR THE TREATMENT OF DYSFUNCTIONS OF THE SOUND SYSTEM AND OLFACTORY
TW201309298A (en) 2011-02-04 2013-03-01 Actelion Pharmaceuticals Ltd Pharmaceutical composition for treating malignant glioma
DE14721256T1 (en) * 2013-04-22 2017-03-16 Sandoz Ag PHARMACEUTICAL COMPOSITIONS WITH CRYSTALLINE MACITENTANE
NZ714963A (en) 2013-06-13 2020-07-31 Akebia Therapeutics Inc Compositions and methods for treating anemia
WO2014198178A1 (en) * 2013-06-14 2014-12-18 杭州普晒医药科技有限公司 Macitentan crystal, preparation method therefor, pharmaceutical composition and use thereof
US20170158645A1 (en) * 2014-07-15 2017-06-08 Olon S.P.A. Amorphous form and new crystalline forms of macitentan
DK3172209T3 (en) 2014-07-25 2021-02-22 Novartis Ag TABLET FORMULATION WITH 2-FLUORO-N-METHYL-4- [7- (QUINOLIN-6-YLMethyl) IMIDAZO [1,2-B] [1,2,4] TRIAZIN-2-YL] BENZAMIDE
CN105388244B (en) * 2015-12-10 2017-03-08 合肥久诺医药科技有限公司 A kind of ACT-064992 is about the HPLC (high performance liquid chromatography) of material
WO2018153925A1 (en) 2017-02-22 2018-08-30 Amneal Pharmaceuticals Company Gmbh Stable pharmaceutical compositions comprising macitentan
SI3897646T1 (en) 2018-12-21 2024-08-30 ACTELION PHARMACEUTICALS lTD, Macitentan for the treatment of pulmonary arterial hypertension
TW202042818A (en) 2019-01-25 2020-12-01 瑞士商艾克泰聯製藥有限公司 Pharmaceutical composition for the treatment of chronic thromboembolic pulmonary hypertension
RS66002B1 (en) 2019-05-22 2024-10-31 Wuxi Biocity Biopharmaceutics Co Ltd Crystal form of pyrimidine sulfonamide compound and preparation method therefor
AU2020309223B2 (en) 2019-07-05 2025-05-29 TECNIMEDE - Sociedade Técnico-Medicinal, S.A Compressed macitentan compositions, methods and uses thereof
TW202133851A (en) 2019-11-29 2021-09-16 瑞士商艾克泰聯製藥有限公司 Methods of treating pulmonary arterial hypertension
WO2022238375A1 (en) 2021-05-11 2022-11-17 Actelion Pharmaceuticals Ltd Methods of treating pulmonary hypertension
TW202317119A (en) * 2021-06-11 2023-05-01 瑞士商艾克泰聯製藥有限公司 Dispersible tablet for oral administration
CN117835971A (en) 2021-08-25 2024-04-05 巴斯夫欧洲公司 Direct compression tableting excipient composition
WO2023038600A1 (en) * 2021-09-07 2023-03-16 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A capsule formulation comprising macitentan
EP4154873A1 (en) 2021-09-22 2023-03-29 Sanovel Ilac Sanayi Ve Ticaret A.S. The tablet comprising macitentan

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945098A (en) 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
JPH04103525A (en) 1990-08-22 1992-04-06 Sanwa Kagaku Kenkyusho Co Ltd Production of sustainable pharmaceutical preparation for poorly water-soluble medicine
RU2086544C1 (en) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Benzenesulfonamide derivatives of pyrimidine or their salts, pharmaceutical composition for treatment of diseases associated with endothelin activity
CA2124690C (en) 1992-10-02 2007-09-11 Thomas Osterberg Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
US5811120A (en) 1994-03-02 1998-09-22 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
TW442301B (en) 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
ATE201202T1 (en) 1995-12-20 2001-06-15 Yamanouchi Pharma Co Ltd ARYLETHENESULFONAMIDE DERIVATIVES AND MEDICATIONS CONTAINING SAME
JPH103525A (en) 1996-06-14 1998-01-06 Dainippon Printing Co Ltd IC card, instruction code storage method, and instruction code execution method
AR017426A1 (en) 1997-12-08 2001-09-05 Smithkline Beecham Corp ACID MONOARGININYL SALT (E) -3- [1-N-BUTIL-5- [2- (2-CARBOXIFENIL) METOXI-4-CHLOROPHENYL] -1H-PIRAZOL-4-IL] -2 - [(5- METOXI-2,3-DIHIDROBENZOFURAN-6-IL) METHYL] -PROP-2-ENOICO, PHARMACEUTICAL COMPOSITION CONTAINING IT, ITS USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND PROCEDURE FOR PREPARATION
ATE219658T1 (en) 1998-03-06 2002-07-15 Eurand Int QUICKLY DISSOLVING TABLET
US20010014352A1 (en) * 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
US20040062803A1 (en) * 1999-12-22 2004-04-01 Hedden David B. Sustained-release formulation of a cyclooxygenase-2 inhibitor
CZ20022293A3 (en) * 1999-12-31 2003-04-16 Texas Biotechnology Corporation Sulfonamides and their derivatives adjusting endothelin activity
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
JP2001335469A (en) 2000-05-26 2001-12-04 Lion Corp Manufacturing method of solid preparation
HUP0301802A3 (en) 2000-06-28 2009-04-28 Teva Pharma Process for producing carvedilol, crystalline carvedilol, process for producing it and pharmaceutical composition containing it
US7125565B2 (en) 2000-12-01 2006-10-24 Kyowa Hakko Kogyo Co., Ltd. Composition improved in the solubility or oral absorbability
CN1486302A (en) 2000-12-07 2004-03-31 CV���ƹ�˾ Substituted 1,3, 5-triazines and pyrimidines as ABCA-1 potentiating compounds against coronary artery disease or arteriosclerosis
KR100819668B1 (en) * 2000-12-18 2008-04-04 액테리온 파마슈티칼 리미티드 Novel pyrimidine-sulfuramides
FR2819720B1 (en) * 2001-01-22 2004-03-12 Fournier Lab Sa NEW FENOFIBRATE TABLETS
JP3930290B2 (en) 2001-09-12 2007-06-13 富士フイルム株式会社 Photothermographic material and thermal development method using the same
KR20030041577A (en) * 2001-11-20 2003-05-27 디디에스텍주식회사 Solid dispersions containing substituted cyclodextrin and insoluble drug and their preparations
JP2006502083A (en) * 2002-01-07 2006-01-19 ファルマシア コーポレイション Drug mixture with increased dissolution rate
MXPA04007737A (en) 2002-02-11 2004-10-15 Pfizer Nicotinamide derivatives useful as pde4 inhibitors.
IL163642A0 (en) * 2002-02-26 2005-12-18 Astrazeneca Ab Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
GB0204771D0 (en) 2002-02-28 2002-04-17 Phoqus Ltd Fast disintegrating tablets
WO2004067008A1 (en) 2003-01-28 2004-08-12 Takeda Pharmaceutical Company Limited Receptor agonists
MXPA05009098A (en) 2003-02-25 2005-11-17 Lilly Co Eli Crystalline non-solvated 1- (4-(2- piperidinylethoxy) phenoxy)- 2-(4 -methanesulfonylphenyl) -6- hydroxynaphthalene hydrochloride.
EP1697382A4 (en) 2003-12-10 2008-11-05 Activbiotics Inc Rifamycin analogs and uses thereof
US7094081B1 (en) * 2005-03-24 2006-08-22 Delphi Technologies, Inc. Electrical connector assembly
KR101313395B1 (en) 2005-09-12 2013-10-02 액테리온 파마슈티칼 리미티드 Stable pharmaceutical composition comprising a pyrimidine-sulfamide
AR062501A1 (en) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd THERAPEUTIC COMPOSITIONS
KR20100132489A (en) 2008-02-20 2010-12-17 액테리온 파마슈티칼 리미티드 Combination comprising paclitaxel to treat ovarian cancer
HUE047767T2 (en) 2008-08-13 2020-05-28 Actelion Pharmaceuticals Ltd Therapeutic preparations containing macitentan
TW201309298A (en) 2011-02-04 2013-03-01 Actelion Pharmaceuticals Ltd Pharmaceutical composition for treating malignant glioma

Also Published As

Publication number Publication date
BRPI0615898B1 (en) 2020-02-18
US10117870B2 (en) 2018-11-06
US20180263980A1 (en) 2018-09-20
MY151003A (en) 2014-03-31
CA2621273C (en) 2014-07-29
TWI323661B (en) 2010-04-21
CA2621273A1 (en) 2007-03-22
NO341325B1 (en) 2017-10-16
US20080233188A1 (en) 2008-09-25
RU2008113869A (en) 2009-10-20
TW200803860A (en) 2008-01-16
US20130190336A1 (en) 2013-07-25
US9265762B2 (en) 2016-02-23
JP4955685B2 (en) 2012-06-20
JP2009519893A (en) 2009-05-21
NZ567188A (en) 2011-04-29
WO2007031933A3 (en) 2007-10-18
US20210186966A1 (en) 2021-06-24
SI1928409T1 (en) 2012-12-31
PL1928409T3 (en) 2013-02-28
HK1121950A1 (en) 2009-05-08
WO2007031933A2 (en) 2007-03-22
AU2006290309B2 (en) 2012-04-05
RU2424805C2 (en) 2011-07-27
JP5054061B2 (en) 2012-10-24
EP2292209A2 (en) 2011-03-09
US10946015B2 (en) 2021-03-16
US20160136163A1 (en) 2016-05-19
DK1928409T3 (en) 2012-11-05
PT1928409E (en) 2012-11-27
CY1113395T1 (en) 2016-06-22
EP2292209A3 (en) 2011-05-04
IL190072A (en) 2013-08-29
US11648249B2 (en) 2023-05-16
US20100004274A1 (en) 2010-01-07
EP1928409B1 (en) 2012-09-12
AU2006290309A1 (en) 2007-03-22
CN101262847B (en) 2010-11-24
ZA200802947B (en) 2009-12-30
HRP20120957T1 (en) 2012-12-31
IL190072A0 (en) 2008-08-07
ES2393117T3 (en) 2012-12-18
JP2009235073A (en) 2009-10-15
CN101262847A (en) 2008-09-10
US8367685B2 (en) 2013-02-05
EP1928409A2 (en) 2008-06-11
KR20080055897A (en) 2008-06-19
KR101313395B1 (en) 2013-10-02
BRPI0615898B8 (en) 2021-05-25
BRPI0615898A2 (en) 2011-05-31

Similar Documents

Publication Publication Date Title
NO20081724L (en) Stable pharmaceutical composition comprising a pyrimidine sulfamide
MX342683B (en) Cyclopamine analogs.
CR8824A (en) DERIVATIVES OF 2-CARBAMIDA-4-FENILTIAZOL, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
UA94833C2 (en) Substituted bicyclolactams
ATE493386T1 (en) TRANS-3-AZA-BICYCLO-Ä3.1.0Ü-HEXANE DERIVATIVES
BRPI0715579A2 (en) "compound, pharmaceutical composition and use of a compound"
PT1940839E (en) Pyridopyrimidinone inhibitors of pi3kalpha
ECSP099413A (en) BASED COMPOUNDS OF 4 - Phenyl - 6 - (2,2,2 - Trifluoro - 1 - Phenylethoxy) pyrimidine AND METHODS FOR USE
CR9602A (en) NEW DERIVATIVES OF 2,4-DIANILINPIRIMIDINAS, ITS PREPARATION, AS MEDICINES, PHARMACEUTICAL COMPOSITIONS AND PARTICULARLY AS IKK INHIBITORS
DE602004008098D1 (en) SUBSTITUTED 2H-Ä1,2,4ÜTRIAZOLOÄ4,3-AÜPYRAZINE AS GSK-3 INHIBITORS
HRP20120323T1 (en) Diarylhydantoin compounds
NO20090175L (en) Stable laquinimod compositions
NO20082090L (en) Pyridopyrimidinone inhibitors of P13K alpha
MX372721B (en) HALOGENATED ANALOGUES OF ANTIFIBROTIC AGENTS.
MX2009008028A (en) Benzofuran antiparasitic agents.
CR9391A (en) DERIVATIVES OF INDANIL-PIPERAZINAS, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
EA200700365A1 (en) INDOL-2-CARBOXAMIDINE DERIVATIVES AS ANTAGONISTS OF NMDA RECEPTOR
MA32834B1 (en) Aminocyclopentaneicarboxamide 3 acts as a shimokin receptor modulator
EA200700997A1 (en) 2,5- and 2,6-DESIGNATED BENZAZOL ANALOGUES, USEFUL AS A PROTEINKINAZ INHIBITOR
NO20081587L (en) Aerosol formulation for inhalation
EA200801365A1 (en) SUBSTITUTED 5-PHENYL-3,6-DIGIDRO-2-OXO-6H-1,3,4-TIADIAZINS
EA200801366A1 (en) DERIVATIVES 3,6-DIGIDRO-2-OXO-6N-1,3,4-TIADIAZINA
DE602007005387D1 (en) PTORS
ATE546448T1 (en) UROTENSIN II RECEPTOR ANTAGONISTS
MX2010007929A (en) Novel imidazolinylmethyl aryl sulfonamides.